identif
specif
immunogen
candid
effect
activ
appropri
pathway
neutral
antibodi
product
fundament
vaccin
design
use
monoclon
antibodi
neutral
hcv
vitro
demonstr
recogn
epitop
map
residu
protein
also
found
epitop
residu
crucial
antibodi
bind
residu
within
epitop
engag
interact
host
entri
factor
furthermor
detect
antibodi
defin
amino
acidspecif
similar
plasma
patient
chronic
hcv
infect
time
cours
studi
plasma
sampl
patient
h
wellcharacter
case
posttransfus
hepat
c
show
antibodi
could
detect
sampl
collect
almost
two
year
initi
infect
thu
confirm
immunogen
epitop
vivo
character
neutral
epitop
function
host
entri
factor
interact
enhanc
understand
antibodymedi
neutral
hcv
infect
hepat
c
major
public
health
problem
worldwid
infect
peopl
fail
clear
viru
acut
phase
diseas
becom
chronic
carrier
liver
cirrhosi
develop
chronic
infect
patient
link
high
risk
hepatocellular
carcinoma
later
life
hepat
c
viru
hcv
relat
end
stage
liver
diseas
lead
reason
liver
transplant
unit
state
mani
year
standard
therapi
hepat
c
consist
regimen
pegyl
alpha
interferon
ribavirin
show
limit
success
depend
viral
genotyp
antivir
drug
therapi
recent
augment
fda
approv
two
hcvspecif
proteas
inhibitor
boceprivir
telaprevir
new
drug
combin
achiev
sustain
virolog
respons
rate
close
hcv
genotyp
patient
clinic
trial
new
treatment
promis
higher
cure
rate
especi
difficulttotreat
hcv
genotyp
infect
high
cost
drug
therapi
gener
still
make
option
unafford
develop
countri
develop
safe
effect
hcv
vaccin
remain
import
goal
global
control
hcv
infect
understand
antibodymedi
neutral
hcv
infect
thu
becom
potenti
key
step
toward
vaccin
design
one
major
challeng
elicit
effect
immun
hcv
genet
divers
viru
overcom
variabl
may
requir
product
specif
antibodi
broadli
neutral
hcv
envelop
glycoprotein
long
consid
import
immunogen
target
effort
gener
protect
immun
consider
larg
base
role
protein
facilit
entri
hcv
hepatocyt
via
interact
particular
host
entri
factor
studi
report
monoclon
antibodi
mab
hcvneutral
antibodi
target
highli
conserv
peptid
sequenc
aptysw
protein
residu
studi
also
reveal
region
play
role
interact
host
entri
factor
furthermor
result
show
two
distinct
set
amino
acid
within
epitop
engag
neutral
antibodi
bind
interact
new
find
may
enhanc
understand
antibodymedi
neutral
hcv
infect
monoclon
antibodi
produc
precis
antibodi
columbia
md
accord
standard
procedur
briefli
balbc
mice
inject
intraperiton
recombin
hcv
protein
aa
fuse
human
invivogen
san
diego
ca
mice
produc
high
titer
antibodi
protein
select
cell
fusion
gener
hybridoma
hybrid
cell
secret
hcv
antibodi
clone
expand
cultur
bd
cell
tm
mab
serumfre
medium
bd
bioscienc
san
jose
ca
co
antibodi
product
studi
anonym
patient
plasma
sampl
receiv
nih
deidentifi
number
sequenc
none
sampl
directli
indirectli
link
donor
ident
sampl
collect
accord
protocol
approv
nih
institut
review
board
addit
separ
set
sampl
test
studi
taken
antihcv
posit
plasma
donat
use
gener
antihcv
immunoglobulin
prepar
previous
describ
sampl
neg
hepat
b
surfac
antigen
nonreact
antibodi
hiv
type
alanin
aminotransferas
level
less
twice
upper
limit
normal
research
studi
exempt
irb
rihsc
review
accord
cfr
b
mean
standard
fastmoc
chemistri
peptid
synthes
peptid
synthes
model
appli
biosystem
foster
citi
ca
core
laboratori
center
biolog
evalu
research
fda
describ
previous
biotinyl
peptid
synthes
fmocli
biotinlc
wang
resin
anaspec
san
jose
ca
hcv
construct
span
region
encod
residu
made
pcr
use
specif
primer
pair
clone
mammalian
cell
express
vector
invivogen
singl
site
mutat
construct
introduc
accord
quikchang
sitedirect
mutagenesi
kit
protocol
stratagen
la
jolla
ca
truncat
form
ie
likewis
construct
pcr
specif
primer
pair
remov
region
encod
residu
residu
respect
clone
vector
construct
transient
transfect
individu
cell
lipofectamin
tm
reagent
life
technolog
grand
island
ny
cell
cultur
media
contain
secret
form
express
protein
collect
supernat
analysi
select
antibodi
bind
peptid
random
peptid
phage
display
librari
new
england
biolab
beverli
describ
previous
briefli
phage
incub
mixtur
protein
acoat
magnet
bead
dynabeadsh
protein
life
technolog
min
room
temperatur
allow
suffici
bind
eight
wash
trishcl
buffer
ph
contain
nacl
tween
tbst
bound
phage
elut
complex
glycin
solut
ph
elut
phage
amplifi
host
strain
amplifi
phage
subject
two
addit
round
select
antibodi
titrat
lbagar
plate
dna
singl
phage
plaqu
sequenc
correspond
peptid
sequenc
deduc
dna
sequenc
sequenc
phagedisplay
peptid
hcv
protein
align
determin
extent
similar
biotinyl
peptid
ng
prepar
ml
superblock
block
buffer
thermo
fisher
scientif
rockford
il
ad
well
streptavidinco
plate
thermo
fisher
scientif
incub
room
temperatur
h
plate
wash
time
phosphatebuff
salin
contain
pbst
ph
follow
incub
ml
patient
plasma
dilut
affinitypurifi
dilut
h
room
temperatur
remov
unbound
antibodi
wash
time
pbst
goat
antihuman
peroxidaseconjug
igg
sigmaaldrich
st
loui
mo
dilut
superblock
block
buffer
ad
well
plate
wash
anoth
time
kept
dark
min
ml
tmb
substrat
solut
thermo
fisher
scientif
reaction
stop
ad
ml
h
absorb
nm
well
measur
spectramax
microtit
plate
reader
molecular
devic
sunnyval
ca
biotinyl
peptid
yqpyrvvvlsfellnapatv
deriv
sar
viru
use
neg
control
assay
dilut
nm
read
mean
standard
deviat
obtain
use
cutoff
defin
posit
serumfre
cultur
media
contain
secret
form
protein
mutant
collect
day
transfect
cell
sampl
treat
sd
sampl
load
buffer
heat
min
load
well
nupag
bistri
precast
polyacrylamid
gel
life
technolog
separ
gel
electrophoresi
protein
transfer
onto
nitrocellulos
membran
accord
manufactur
instruct
five
percent
nonfat
dri
milk
pbst
use
block
membran
h
room
temperatur
block
membran
incub
dilut
primari
antibodi
addit
hour
wash
horseradish
peroxidaseconjug
antimous
igg
antibodi
dilut
kpl
gaithersburg
md
use
secondari
antibodi
supersign
west
pico
chemiluminesc
substrat
solut
thermo
scientif
appli
membran
accord
manufactur
protocol
data
collect
fluorchem
e
imag
proteinsimpl
santa
clara
ca
larg
extracellular
domain
human
residu
protein
residu
fuse
gaussia
luciferas
new
england
biolab
human
fc
moieti
invivogen
respect
produc
construct
construct
transient
transfect
separ
cell
later
secret
result
fusion
protein
cell
cultur
medium
amount
protein
cell
cultur
supernat
monitor
either
western
blot
analysi
use
specif
antibodi
human
fc
tag
measur
activ
luciferas
bioluxh
gaussia
luciferas
flex
assay
kit
new
england
biolab
supernat
mlwell
contain
either
mutant
form
incub
microtit
plate
coat
protein
thermo
scientif
room
temperatur
h
wash
pbst
supernat
unit
luciferas
activ
ml
mgreaction
without
ad
well
incub
h
rins
plate
pbst
ml
mixtur
biolux
kit
substrat
buffer
ad
well
bioluminesc
signal
intens
immedi
measur
infinit
micropl
reader
tecan
nnedorf
switzerland
neutral
assay
rluc
viru
gener
insert
renilla
luciferas
gene
previous
describ
genotyp
viru
cellswel
plate
well
flat
bottom
plate
corn
new
york
next
day
ml
cell
cultur
supernat
antibodi
concentr
mgml
serial
dilut
ad
cell
cultur
follow
ad
ml
rluc
viru
incub
hour
cell
lyse
rlu
measur
promega
renilla
luciferas
assay
system
madison
wi
biotek
clariti
micropl
luminomet
winooski
vt
defin
key
residu
hcv
protein
bind
develop
panel
mab
immun
mice
recombin
hcv
protein
residu
base
amino
acid
sequenc
hcv
genotyp
strain
fuse
human
fc
moieti
among
mab
found
neutral
antibodi
reduc
infect
hcv
genotyp
viru
vitro
dosedepend
manner
fig
key
residu
involv
bind
map
initi
screen
random
peptid
phage
display
librari
phage
fig
antibodi
select
preferenti
phage
display
peptid
contain
w
residu
linear
consensu
sequenc
apt
sw
base
analysi
sequenc
homolog
protein
predict
aptysw
protein
like
bind
site
verifi
locat
predict
bind
site
gener
three
ctermin
truncat
form
protein
lack
put
transmembran
domain
residu
fig
western
blot
analysi
show
protein
residu
could
recogn
remov
residu
demonstr
protein
affect
bind
howev
delet
residu
ie
seen
protein
result
loss
bind
fig
result
suggest
segment
residu
sequenc
aptysw
locat
involv
bind
residu
specif
determin
replac
key
contact
residu
predict
phage
display
alanin
glycin
construct
fig
western
blot
analysi
perform
test
specif
effect
substitut
bind
fig
mutat
significantli
affect
bind
wherea
mutat
reduc
bind
data
consist
predict
phage
display
analysi
residu
direct
contact
point
antibodi
also
want
know
whether
predict
bind
site
could
recogn
linear
fashion
sever
bind
site
peptid
contain
residu
chemic
synthes
without
alanin
substitut
posit
fig
elisa
result
show
peptid
contain
mutat
could
recogn
antibodi
equal
well
wildtyp
peptid
howev
antibodi
longer
bound
peptid
replac
alanin
fig
result
confirm
stretch
mgml
antibodi
collect
use
neutral
assay
dilut
seri
monoclon
mous
antibodi
supernat
use
posit
control
percent
neutral
calcul
base
irrelev
mous
antibodi
supernat
residu
form
linear
epitop
neutral
antibodi
examin
possibl
epitop
somehow
involv
hcv
interact
provid
explan
neutral
mechan
devis
luciferas
report
type
assay
help
recombin
protein
monitor
interact
protein
expect
protein
abl
bind
fig
experiment
condit
found
interact
protein
repres
level
luciferas
activ
significantli
weaken
presenc
increas
amount
fig
thu
valid
util
luciferas
assay
blockag
interact
protein
prompt
us
determin
residu
within
epitop
engag
interact
protein
mutat
form
test
abil
bind
luciferas
assay
fig
found
singl
site
mutat
significantli
reduc
bind
protein
ie
respect
compar
wildtyp
thu
confirm
observ
previous
report
meanwhil
bind
appear
less
affect
mutat
survey
sequenc
conserv
amino
acid
residu
across
hcv
strain
deposit
viru
pathogen
databas
analysi
resourc
vipr
http
wwwviprbrcorg
tabl
align
hcv
protein
sequenc
show
four
residu
highli
conserv
intriguingli
residu
found
import
specif
bind
could
replac
amino
acid
particularli
valin
biotinconjug
peptid
contain
amino
acid
protein
chemic
synthes
repres
linear
epitop
specif
substitut
posit
introduc
bold
letter
one
time
hyphen
repres
amino
acid
ident
strain
sequenc
b
detect
bind
epitop
peptid
elisa
biotinlink
peptid
ng
coat
onto
well
plate
precoat
streptavidin
dilut
use
primari
antibodi
hrplink
antimous
antibodi
use
secondari
antibodi
data
obtain
least
three
independ
experi
xaxi
indic
peptid
use
elisa
yaxi
indic
result
absorb
nm
repres
specif
bind
peptid
maintain
interfac
critic
interact
rais
possibl
bind
epitop
could
modifi
viru
contain
substitut
natur
amino
acid
variat
found
high
frequenc
hcv
strain
deposit
vipr
databas
regardless
genotyp
might
otherwis
classifi
fig
ask
variant
behav
bind
interact
protein
seri
sitedirect
mutagenesi
experi
carri
gener
two
type
variat
backbon
protein
strain
fig
western
blot
analysi
show
substitut
valin
residu
significantli
reduc
bind
protein
fig
howev
demonstr
luciferasebas
assay
interact
mutat
affect
substitut
fig
result
suggest
hcv
variant
valin
posit
may
lose
bind
protein
substitut
could
found
strain
databas
n
may
maintain
function
interact
also
includ
variant
substitut
posit
experi
found
protein
substitut
affect
bind
bind
fig
suggest
absolut
requir
bind
inde
either
substitut
could
seen
respect
hcv
strain
n
affect
bind
although
replac
reduc
bind
western
blot
fig
result
suggest
bind
residuespecif
posit
select
residu
posit
unlik
crucial
protein
interact
observ
support
view
least
two
set
amino
acid
within
short
peptid
distinguish
function
ie
recognit
interact
tabl
residu
two
residu
critic
antibodi
bind
residu
residuespecif
manner
critic
antibodi
bind
interact
contrast
requir
interact
antibodi
bind
share
residu
bind
antibodi
like
provid
basi
neutral
activ
exert
fig
order
find
whether
bind
site
immunogen
enough
elicit
epitopespecif
antibodi
cours
natur
hcv
infect
analyz
plasma
sampl
patient
chronic
hcv
infect
elisa
assay
cutoff
base
nm
read
neg
figur
effect
natur
occur
variant
protein
specif
residu
substitut
linear
epitop
bind
interact
residu
deriv
protein
strain
ie
indic
serv
refer
sequenc
bold
letter
show
presenc
specif
residu
posit
hyphen
indic
possibl
amino
acid
posit
although
residu
posit
highli
conserv
among
strain
tabl
preval
strain
contain
specif
residu
bold
letter
vipr
databas
shown
b
reactiv
protein
indic
substitut
determin
western
blot
analysi
secret
form
protein
produc
cell
dilut
hrpconjug
antimous
igg
dilut
use
primari
secondari
antibodi
respect
detect
antifc
dilut
serv
control
c
determin
interact
variant
luciferasebas
bind
assay
xaxi
indic
differ
construct
use
assay
axi
indic
rel
luciferas
activ
repres
direct
interact
control
sar
viru
peptid
use
cutoff
posit
test
plasma
sampl
reactiv
wildtyp
epitop
peptid
residu
mutant
tabl
found
patient
sampl
react
posit
wildtyp
peptid
among
wildtyp
peptidereact
sampl
sampl
also
react
posit
mutant
sampl
neg
result
demonstr
exist
antibodi
patient
hcv
infect
thu
support
notion
epitop
peptid
suffici
immunogen
stimul
host
immun
system
gener
neutral
antibodi
fine
residuespecif
order
determin
time
cours
product
particular
neutral
antibodi
initi
infect
test
presenc
antibodi
serial
plasma
sampl
patient
h
posttransfus
chronic
hepat
c
patient
whose
case
welldocu
three
peptid
includ
wildtyp
mutant
design
defin
specif
antibodi
select
elisa
result
reveal
antibodi
could
detect
day
rel
low
level
fig
level
antibodi
increas
significantli
day
remain
elev
day
conclud
possibl
hepat
c
patient
produc
neutral
antibodi
albeit
chronic
stage
hcv
infect
success
vaccin
reli
often
abil
elicit
neutral
antibodi
human
paradox
natur
cours
hcv
infect
neutral
antibodi
rare
detect
earli
stage
infect
detect
antibodi
essenti
ineffect
vivo
spite
neutral
activ
demonstr
vitro
consequ
patient
establish
persist
hcv
infect
even
presenc
appreci
amount
neutral
antibodi
addit
observ
hcv
variant
reinfect
graft
liver
transplant
patient
poorli
neutral
antibodi
present
pretranspl
plasma
contrast
viral
variant
could
longer
detect
follow
transplant
effici
neutral
observ
support
hypothesi
profil
antibodi
elicit
viru
natur
cours
patient
hcv
infect
combin
high
mutat
rate
viru
determin
ultim
pattern
humor
immun
major
case
result
virusspecif
neutral
antibodi
respons
occur
late
neutral
antibodi
produc
insuffici
amount
halt
infect
line
think
comprehens
studi
clinic
sampl
collect
singlesourc
outbreak
hepat
c
shown
neutral
antibodi
produc
earli
infect
play
import
role
clearanc
hcv
thu
avoid
chronic
present
studi
test
proof
concept
feasibl
defin
hcv
antigen
epitop
could
preferenti
elicit
neutral
antibodi
hcv
addit
show
residu
constitut
linear
bind
site
neutral
antibodi
provid
evid
epitop
also
involv
differ
set
amino
acid
interact
protein
host
entri
factor
result
may
explain
neutral
hcv
realiz
interfac
protein
host
entri
factor
genet
divers
hcv
pose
great
challeng
gener
antibodi
capabl
neutral
variou
hcv
genotyp
least
six
distinct
genotyp
hcv
exhibit
extens
variabl
particularli
within
envelop
gene
differ
approxim
nucleotid
level
even
within
singl
infect
individu
hcv
may
exist
complex
popul
genet
distinct
variant
term
quasispeci
therefor
conserv
residu
protein
directli
involv
viru
entri
would
reason
target
elicit
neutral
antibodi
antibodi
block
experi
inde
shown
sever
region
protein
critic
bind
howev
antibodi
use
experi
conformationsensit
difficult
confirm
whether
observ
inhibitori
effect
interact
protein
result
directli
block
bind
site
protein
antibodymedi
steric
hindranc
despit
difficulti
major
broadli
neutral
conformationsensit
antibodi
report
far
includ
isol
human
appear
recogn
highli
conserv
residu
critic
bind
particular
substitut
posit
alanin
show
two
residu
part
bind
site
also
import
neutral
hcv
sever
antibodi
observ
consist
previou
find
other
use
human
monoclon
antibodi
determin
two
conserv
residu
antibodi
contact
conform
epitop
import
interact
addit
demonstr
natur
occur
amino
acid
variat
appear
linear
epitop
valin
posit
asparagin
threonin
posit
protein
may
repres
potenti
mechan
hcv
escap
neutral
select
incorpor
certain
highli
conserv
residu
short
linear
epitop
previous
suggest
other
confirm
us
studi
take
variant
residu
eg
consider
escap
potenti
might
worthwhil
explor
order
advanc
discoveri
immunogen
effect
produc
neutral
antibodi
hcv
infect
abil
dissect
function
exhibit
residu
within
bind
site
give
us
opportun
monitor
product
antibodi
natur
cours
hcv
infect
correl
presenc
clinic
outcom
observ
delay
product
neutral
antibodi
hcv
infect
weak
neutral
antibodi
respons
protein
chronic
infect
patient
previous
report
other
present
tabl
presenc
antibodi
patient
chronic
hcv
infect
step
step
step
know
reason
delay
neutral
antibodi
product
specul
tertiari
structur
viral
protein
present
surfac
virion
interact
heterodim
instanc
may
prevent
exposur
critic
residu
necessari
antibodi
product
earli
phase
infect
anoth
possibl
escap
variant
may
rapidli
accumul
patient
acut
phase
hcv
infect
could
lead
failur
antibodi
respons
direct
epitop
accord
model
hcv
variant
irrelev
genotyp
may
abl
escap
antibodymedi
neutral
cours
natur
infect
substitut
residu
protein
chang
alanin
valin
posit
serin
asparagin
threonin
posit
associ
antibodi
recognit
without
affect
interact
plan
perform
seri
experi
anim
model
systemat
investig
antibodi
elicit
immun
peptid
contain
specif
substitut
could
affect
infect
viru
breadth
antibodymedi
neutral
